Business Context and Reporting Period
This Form 8-K Current Report from Indivior Pharmaceuticals, Inc. (INDV) covers events occurring on May 13, 2026, and effective June 1, 2026. The filing details the results of the Company's virtual Annual Meeting of Stockholders and announces a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel changes rather than financial performance data.
Material Changes
Executive Leadership Change
- Position Elimination: Effective June 1, 2026, the Company will eliminate the position of Chief Scientific Officer.
- Dr. Christian Heidbreder: Will transition to an advisory capacity on special projects reporting to the CEO through December 31, 2026.
- Termination Terms: His employment will terminate on December 31, 2026, treated as a termination without cause under his existing agreement.
Annual Meeting Results
- Shareholder Participation: 100,407,722 shares were present in person or by proxy out of 121,922,058 shares entitled to vote.
- Director Elections: All eight nominees were elected. Daniel Ninivaggi received the highest number of "Against" votes (5,366,849) compared to other nominees.
- Say-on-Pay: Approved with 90,364,566 votes For and 1,324,996 votes Against.
- Say-on-Frequency: Shareholders voted for an annual frequency (91,848,954 votes For 1 Year).
- Auditor Ratification: PricewaterhouseCoopers LLP US (PwC) was ratified as the independent auditor for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure of the executive departure. The Board has committed to holding annual "say-on-pay" votes based on the shareholder advisory vote results.
Investor Verification Checklist
- Verify the specific financial implications of Dr. Heidbreder's termination without cause in future filings (e.g., severance costs).
- Review the definitive Proxy Statement filed on March 27, 2026, for detailed background on the director nominees and executive compensation.
- Monitor future 10-Q or 10-K filings for the impact of the Chief Scientific Officer role elimination on R&D pipelines.
- Confirm the exact number of shares present at the meeting, as the source text contains a potential typographical error ("100,407,7225").